Shots:
- Novartis has entered into an agreement to acquire Excellergy, incl. its asset Exl-111, strengthening Novartis immunology strategy in food allergy & other IgE-driven diseases
- As per the deal, Novartis will acquire Excellergy for ~$2B, incl. upfront & milestone payments, with closing expected in H2’26
- EXL-111 is engineered to dissociate receptor-bound IgE, enabling faster & deeper FcεRIα downregulation, with preclinical & early P-I PK data indicating a differentiated profile with sustained exposure aligned with its half-life–extended design
Ref: Novartis | Image: Excellergy | Press Release
Related News: Novartis to Acquire Pikavation Therapeutics from Synnovation for ~$3B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
